米非司酮单用与联合宫瘤消胶囊对子宫腺肌症患者的影响  

Effects of Only Mifepristone and Its Combination with Gongliuxiao Capsules on the Patients with Adenomyosis

作　　者：李著艳 马亚琳 龚宝兰 LI Zhuyan;MA Yalin;GONG Baolan(Shiyan City People′s Hospital/Department of Gynecology,Affiliated People′s Hospital of Hubei University of Medicine,Shiyan 442000,China)

机构地区：[1]十堰市人民医院/湖北医药学院附属人民医院妇科

出　　处：《西部中医药》2019年第7期92-95,共4页Western Journal of Traditional Chinese Medicine

基　　金：国家自然科学基金项目(编号81272866)

摘　　要：目的:探讨非司酮单用与联合宫瘤消胶囊对子宫腺肌症(adenomyosis,AM)患者痛经、子宫体积、CA125及复发率的影响。方法:将AM患者76例用随机数字表法分为观察组与对照组各38例,对照组给予米非司酮治疗,观察组在对照组治疗的基础上给予宫瘤消胶囊治疗,治疗3个月。结果:2组患者子宫体积治疗后小于治疗前(P<0.05),观察组治疗后子宫体积小于对照组(P<0.05)。治疗后2组患者痛经评分均低于治疗前(P<0.05),观察组痛经评分低于对照组(P<0.05)。治疗后观察组与对照组患者血清CA125分别为(15.63±5.29)U/mL和(24.13±4.19)U/mL,低于治疗前的(25.65±5.34)U/mL和(25.64±5.21)U/mL(P<0.05),治疗后观察组血清CA125低于对照组(P<0.05)。观察组与对照组随访6个月的复发率分别为0.0%(0/38)和15.8%(6/38),观察组复发率低于对照组(χ2=5.398,P<0.05)。结论:相对于米非司酮,米非司酮联合宫瘤消胶囊治疗AM能缓解患者痛经,促进缩小子宫体积,抑制CA125的表达,减少复发率。Objective:To discuss the effects of only mifeprinstone and its combination with Gongliuxiao capsules on dysmenorrhea,uterine volume,CA125 and the relapse of the patients suffering adenomyosis(AM).Methods:All 76 patients were allocated to the observation group and the control group using random number table method,38 cases each group,the control group was treated with mifeprinstone,and the observation group was given Gongliuxiao capsules based on the therapy the control group accepted,the course was three months.Results:Uterine volume of both groups after treating was smaller than that before treating(P<0.05),the observation group after treating was smaller than the control group in uterine volume(P<0.05).After treating,dysmenorrhea scores of both groups were less than these before treating(P<0.05),the observation group was lower than the control group in dysmenorrhea scores(P<0.05).After treating,CA125 of the observation group and the control group were(15.63±5.29)U/mL and(24.13±4.19)U/mL,obviously lower than(25.65±5.34)U/mL and(25.64±5.21)U/mL before treating(P<0.05),after treating,the observation group was lower than the control group in serum CA125(P<0.05).The relapse rates of the observation group and the control group in six-month follow-ups were 0.0%(0/38)and 15.8%(6/38),the recurrence rate of the observation group was lower than that of the control group(χ2=5.398,P<0.05).Conclusion:Compared with mifeprinstone,its combination with Gongliuxiao capsules could mitigate dysmenorrhea,promote the reduction of uterine volume,inhibit the expressions of CA125 and reduce the relapse.

关 键 词：子宫腺肌症 痛经 CA125 米非司酮 宫瘤消胶囊 

分 类 号：R271[医药卫生—中医妇科学]